FDA clears hyaluronic acid rectal spacer for use during prostate radiotherapy
June 15th 2022Barrigel, which is made from Non-Animal Stabilized Hyaluronic Acid (NASHA), is used to separate and increase the distance between the anterior rectal wall and the prostate when the patient is receiving radiotherapy.
Dr. Armstrong on recent ARCHES data in metastatic hormone-sensitive prostate cancer
June 6th 2022“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.
Dr. Kibel discusses TRUS-guided and transperineal prostate biopsy
June 2nd 2022"We're all very aware of the impact that prostate-specific antigen [PSA] has had on screening for prostate cancer. What's underappreciated is how the biopsy technique pivoted at about the same time," says Adam S. Kibel, MD.
At a glance: Single-port robot-assisted transvesical prostatectomies
June 1st 2022“Using the single-port robot with the transvesical approach allows us to go directly into the bladder, this means that we avoid the intraperitoneal cavity, which is not feasible with the multiport approach. This has led to less pain and postoperative ileus because the bowels stay intact,” says Jihad Kaouk, MD.
Urology Times 50 Innovations Series: Dr. Jennifer Linehan on HIFU for prostate cancer
May 25th 2022"In trying to localize and focalize the treatment on just the lesion of prostate cancer, HIFU was incredibly powerful in the sense that it really allowed you to do that with great precision," said Jennifer Linehan, MD.
Sipuleucel-T: An innovative immunotherapy option for metastatic castration-resistant prostate cancer
May 19th 2022In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kelvin A. Moses, MD, PhD, discusses the prostate cancer immunotherapy treatment sipuleucel-T (Provenge).